Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 22.79
QCOR's Cash to Debt is ranked higher than
72% of the 891 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. QCOR: 22.79 )
QCOR' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 22.79

Equity to Asset 0.57
QCOR's Equity to Asset is ranked higher than
64% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. QCOR: 0.57 )
QCOR' s 10-Year Equity to Asset Range
Min: -0.11   Max: 0.95
Current: 0.57

-0.11
0.95
F-Score: 7
Z-Score: 13.88
M-Score: -1.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 55.05
QCOR's Operating margin (%) is ranked higher than
99% of the 753 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. QCOR: 55.05 )
QCOR' s 10-Year Operating margin (%) Range
Min: -1200   Max: 60.45
Current: 55.05

-1200
60.45
Net-margin (%) 36.63
QCOR's Net-margin (%) is ranked higher than
97% of the 753 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. QCOR: 36.63 )
QCOR' s 10-Year Net-margin (%) Range
Min: -1033.33   Max: 75.52
Current: 36.63

-1033.33
75.52
ROE (%) 73.27
QCOR's ROE (%) is ranked higher than
99% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. QCOR: 73.27 )
QCOR' s 10-Year ROE (%) Range
Min: -229.06   Max: 122.15
Current: 73.27

-229.06
122.15
ROA (%) 39.74
QCOR's ROA (%) is ranked higher than
98% of the 852 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. QCOR: 39.74 )
QCOR' s 10-Year ROA (%) Range
Min: -91.94   Max: 78.31
Current: 39.74

-91.94
78.31
ROC (Joel Greenblatt) (%) 1386.06
QCOR's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -214.14 vs. QCOR: 1386.06 )
QCOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1630.53   Max: 14304.25
Current: 1386.06

-1630.53
14304.25
Revenue Growth (%) 94.00
QCOR's Revenue Growth (%) is ranked higher than
99% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. QCOR: 94.00 )
QCOR' s 10-Year Revenue Growth (%) Range
Min: -12.2   Max: 94.3
Current: 94

-12.2
94.3
EBITDA Growth (%) 106.40
QCOR's EBITDA Growth (%) is ranked higher than
99% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. QCOR: 106.40 )
QCOR' s 10-Year EBITDA Growth (%) Range
Min: -62.5   Max: 117.8
Current: 106.4

-62.5
117.8
EPS Growth (%) 106.60
QCOR's EPS Growth (%) is ranked higher than
99% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. QCOR: 106.60 )
QCOR' s 10-Year EPS Growth (%) Range
Min: -52.5   Max: 106.6
Current: 106.6

-52.5
106.6
» QCOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

QCOR Guru Trades in Q2 2013

HOTCHKIS & WILEY 475,700 sh (New)
John Hussman 150,000 sh (New)
Chuck Royce 37,200 sh (+481.25%)
Jim Simons 894,000 sh (+29.38%)
Steven Cohen Sold Out
Bernard Horn Sold Out
Joel Greenblatt 170,683 sh (-10.66%)
» More
Q3 2013

QCOR Guru Trades in Q3 2013

Steven Cohen 32,052 sh (New)
Paul Tudor Jones 6,100 sh (New)
Chuck Royce 44,100 sh (+18.55%)
Joel Greenblatt 190,961 sh (+11.88%)
John Hussman 150,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Jim Simons 874,700 sh (-2.16%)
» More
Q4 2013

QCOR Guru Trades in Q4 2013

John Paulson 731,410 sh (New)
Steven Cohen 520,938 sh (+1525.29%)
Paul Tudor Jones 10,000 sh (+63.93%)
Joel Greenblatt 296,803 sh (+55.43%)
Chuck Royce 48,200 sh (+9.3%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons 769,400 sh (-12.04%)
» More
Q1 2014

QCOR Guru Trades in Q1 2014

David Dreman 806 sh (New)
Joel Greenblatt 335,494 sh (+13.04%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 35,000 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones 9,200 sh (-8%)
Steven Cohen 416,600 sh (-20.03%)
Chuck Royce 32,200 sh (-33.2%)
Jim Simons 445,400 sh (-42.11%)
» More
» Details

Insider Trades

Latest Guru Trades with QCOR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-03-31 Sold Out 0.2%$50.19 - $79.46 $ 93.4947%0
David Dreman 2014-03-31 New Buy$50.19 - $79.46 $ 93.4947%806
John Paulson 2013-12-31 New Buy0.2%$51.69 - $69.73 $ 93.4958%731410
Joel Greenblatt 2013-12-31 Add 55.43%0.14%$51.69 - $69.73 $ 93.4958%296803
John Hussman 2013-06-30 New Buy0.31%$27.31 - $47.46 $ 93.49164%150000
Joel Greenblatt 2012-12-31 Add 57.57%0.11%$19.36 - $30.06 $ 93.49266%185698
Ron Baron 2012-09-30 Sold Out 0.33%$17.83 - $57.64 $ 93.49126%0
Joel Greenblatt 2012-09-30 New Buy0.15%$17.83 - $57.64 $ 93.49126%117854
Ron Baron 2012-03-31 Add 107.64%0.12%$33.53 - $42.14 $ 93.49169%1010400
Ron Baron 2011-12-31 New Buy0.13%$26.36 - $45.59 $ 93.49138%486600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Questcor Pharmaceuticals Inc

Baron Funds Comments on Questcor Pharmaceuticals Inc. - Dec 07, 2012

Shares of Questcor Pharmaceuticals, Inc. (QCOR) were the biggest detractor in the quarter.The company sells a single drug for which it has expanded applications to drive rapid growth. Our research uncovered some red flags which led us to sell out of our position in the quarter. Subsequent to our exit, the stock fell significantly, so I credit our work and instinct for avoiding a bigger loss.

From Baron Funds third quarter letter.


Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
QCOR's P/E(ttm) is ranked higher than
97% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 17.90 )
QCOR' s 10-Year P/E(ttm) Range
Min: 6.47   Max: 88.1
Current: 17.9

6.47
88.1
P/B 12.30
QCOR's P/B is ranked higher than
60% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 5.83 vs. QCOR: 12.30 )
QCOR' s 10-Year P/B Range
Min: 1.87   Max: 30
Current: 12.3

1.87
30
P/S 6.30
QCOR's P/S is ranked higher than
84% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. QCOR: 6.30 )
QCOR' s 10-Year P/S Range
Min: 1.08   Max: 16.53
Current: 6.3

1.08
16.53
PFCF 14.80
QCOR's PFCF is ranked higher than
97% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 14.80 )
QCOR' s 10-Year PFCF Range
Min: 4.86   Max: 64
Current: 14.8

4.86
64
EV-to-EBIT 11.20
QCOR's EV-to-EBIT is ranked higher than
97% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 11.20 )
QCOR' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 180.6
Current: 11.2

3.5
180.6
PEG 0.20
QCOR's PEG is ranked higher than
100% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.20 )
QCOR' s 10-Year PEG Range
Min: 0.14   Max: 0.48
Current: 0.2

0.14
0.48
Shiller P/E 46.30
QCOR's Shiller P/E is ranked higher than
95% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 46.30 )
QCOR' s 10-Year Shiller P/E Range
Min: 14.58   Max: 202.33
Current: 46.3

14.58
202.33

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
QCOR's Dividend Yield is ranked higher than
62% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. QCOR: 1.30 )
QCOR' s 10-Year Dividend Yield Range
Min: 0.65   Max: 1.9
Current: 1.3

0.65
1.9
Dividend Payout 0.21
QCOR's Dividend Payout is ranked higher than
98% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.21 )
QCOR' s 10-Year Dividend Payout Range
Min: 0.16   Max: 0.31
Current: 0.21

0.16
0.31
Yield on cost (5-Year) 1.30
QCOR's Yield on cost (5-Year) is ranked higher than
61% of the 170 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. QCOR: 1.30 )
QCOR' s 10-Year Yield on cost (5-Year) Range
Min: 0.65   Max: 1.9
Current: 1.3

0.65
1.9
Share Buyback Rate 1.70
QCOR's Share Buyback Rate is ranked higher than
97% of the 719 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. QCOR: 1.70 )
QCOR' s 10-Year Share Buyback Rate Range
Min: 3   Max: -34.5
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 99.50
QCOR's Price/Net Current Asset Value is ranked higher than
73% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 98.06 vs. QCOR: 99.50 )
QCOR' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 85
Current: 99.5

4.5
85
Price/Tangible Book 24.60
QCOR's Price/Tangible Book is ranked higher than
61% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. QCOR: 24.60 )
QCOR' s 10-Year Price/Tangible Book Range
Min: 2.63   Max: 81.14
Current: 24.6

2.63
81.14
Price/DCF (Projected) 2.30
QCOR's Price/DCF (Projected) is ranked higher than
96% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 2.30 )
QCOR' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 14.07
Current: 2.3

1
14.07
Price/Median PS Value 1.40
QCOR's Price/Median PS Value is ranked higher than
76% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 1.99 vs. QCOR: 1.40 )
QCOR' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 2.76
Current: 1.4

0.27
2.76
Price/Peter Lynch Fair Value 0.70
QCOR's Price/Peter Lynch Fair Value is ranked higher than
100% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 0.70 )
QCOR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.26   Max: 3.1
Current: 0.7

0.26
3.1
Price/Graham Number 4.40
QCOR's Price/Graham Number is ranked higher than
89% of the 953 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QCOR: 4.40 )
QCOR' s 10-Year Price/Graham Number Range
Min: 1.2   Max: 17
Current: 4.4

1.2
17
Earnings Yield (Greenblatt) 8.90
QCOR's Earnings Yield (Greenblatt) is ranked higher than
80% of the 397 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. QCOR: 8.90 )
QCOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 28.7
Current: 8.9

0.6
28.7
Forward Rate of Return (Yacktman) 85.38
QCOR's Forward Rate of Return (Yacktman) is ranked higher than
100% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -9.71 vs. QCOR: 85.38 )
QCOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -76   Max: 86.3
Current: 85.38

-76
86.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QPH.Germany
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.
» More Articles for QCOR

Headlines

Articles On GuruFocus.com
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
8 Stocks Trying to Be 'Good' by Raising Their Dividends Oct 14 2013 
4 Top-Performing Healthcare Dividend Stocks with Single-Digit P/Es Jul 02 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
comment on QCOR Apr 11 2013 
My 3 Favorite High-Yielding Ex-Dividend Stocks for April and 45 Additional to Consider Mar 29 2013 
Weekly Guru Bargains Highlights: HAE, DLTR, QCOR, MTX, AMD Jan 21 2013 
Weekly Guru Bargains Highlights: WCRX, IOC, QCOR, PWE, PGH Dec 30 2012 
Baron Funds Comments on Questcor Pharmaceuticals Inc. Dec 07 2012 


More From Other Websites
Questcor Reveals Adverse Events Data for Acthar for First Time Jul 10 2014
Questcor's Acthar: Refuting A Long's Optimism With Irrefutable Facts Jul 10 2014
QUESTCOR PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 10 2014
Questcor's Acthar Gel: Clinical Usage Suggests Efficacy Jul 10 2014
Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today Jul 07 2014
What Stocks Top Funds Are Buying Now Jul 02 2014
Questcor And Mallinckrodt: The Good, The Bad, And The Ugly Jun 30 2014
Hey Mallinckrodt, Pay Close Attention - UnitedHealth Just Slammed Questcor's Acthar Jun 30 2014
The FDA Owes Us An Answer On Questcor's Acthar Jun 25 2014
Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and... Jun 23 2014
Aging stinks, so at least make some money from it Jun 23 2014
[$$] Follow Up Jun 21 2014
Top Value Funds Vs. Top Growth Funds Jun 17 2014
Questcor: Another Serious Reason To Be A Skeptic Jun 17 2014
Mallinckrodt merger proxy doesn't disclose Questcor risks, NY Times reports Jun 13 2014
Questcor's 'Buyout' Could Fall Through Jun 06 2014
Mallinckrodt, Questcor both down after Cigna comments on Acthar Gel Jun 05 2014
Lannett Tops Trio Of Medical Small Cap Leaders Jun 05 2014
Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts Jun 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Cgrain@google
ReplyCgrain@google - 6 months ago
QCOR has legal issues that need to be resolved.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide